[go: up one dir, main page]

ES2097847T3 - Inhibidores de encefalinasa y eca con un radical carboxialquilo. - Google Patents

Inhibidores de encefalinasa y eca con un radical carboxialquilo.

Info

Publication number
ES2097847T3
ES2097847T3 ES92116575T ES92116575T ES2097847T3 ES 2097847 T3 ES2097847 T3 ES 2097847T3 ES 92116575 T ES92116575 T ES 92116575T ES 92116575 T ES92116575 T ES 92116575T ES 2097847 T3 ES2097847 T3 ES 2097847T3
Authority
ES
Spain
Prior art keywords
hydrogen
alkyl
encephalinase
inhibitors
carboxialkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92116575T
Other languages
English (en)
Inventor
Alan M Warshawsky
Gary A Flynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2097847T3 publication Critical patent/ES2097847T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA EN DONDE B1 Y B2 SON CADA UNO, INDEPENDIENTEMENTE, HIDROGENO; HIDROXI; OR2 EN DONDE R2 ES ALKILO C1-C4 O UN GRUPO AR-Y EN DONDE AR ES ARILO E Y ES HIDROGENO O ALKILO C1-C4; O DONDE B1 Y B2 SE ENCUENTRAN UNIDOS A ATOMOS DE CARBONO ADYACENTES, B1 Y B2 SE PUEDEN TOMAR JUNTOS CON DICHOS CARBONOS ADYACENTES PARA FORMAR UN ANILLO DE BENCENO O METILENODIOXI; A ES UN ENLACE, METILENO U OXIGENO, AZUFRE O NR4 O NCOR5 EN DONDE R4 ES HIDROGENO, UN ALKILO C1-C4 O UN GRUPO AR-Y 1-C10 O UN GRUPO AR-Y-; R3 ES HIDROGENO O -CH2OC(O)C(CH3)3; R1 ES HIDROGENO, ALKILO C1-C4 O -CH2OC(O)-C(CH3)3; Y N ES UN ENTERO DE 1 A 3, QUE SON UTILES COMO INHIBIDORES DE LA ENCEFALINASA Y DE LAS ACE.
ES92116575T 1991-09-27 1992-09-28 Inhibidores de encefalinasa y eca con un radical carboxialquilo. Expired - Lifetime ES2097847T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76728191A 1991-09-27 1991-09-27

Publications (1)

Publication Number Publication Date
ES2097847T3 true ES2097847T3 (es) 1997-04-16

Family

ID=25079018

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92116575T Expired - Lifetime ES2097847T3 (es) 1991-09-27 1992-09-28 Inhibidores de encefalinasa y eca con un radical carboxialquilo.

Country Status (17)

Country Link
US (1) US5472959A (es)
EP (1) EP0534492B1 (es)
JP (1) JP3173673B2 (es)
KR (1) KR100273734B1 (es)
AT (1) ATE146482T1 (es)
AU (1) AU657794B2 (es)
CA (1) CA2078759C (es)
DE (1) DE69216026T2 (es)
DK (1) DK0534492T3 (es)
ES (1) ES2097847T3 (es)
FI (1) FI101304B1 (es)
GR (1) GR3022654T3 (es)
HU (1) HU214596B (es)
IL (1) IL103265A (es)
NO (1) NO300844B1 (es)
NZ (1) NZ244442A (es)
ZA (1) ZA927211B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534363B1 (en) * 1991-09-27 1997-07-09 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP3460838B2 (ja) * 1992-02-14 2003-10-27 メレルファーマスーティカルズインコーポレイテッド エンケファリナーゼ及びａｃｅの阻害剤として有用な，アミノアセチルメルカプトアセチルアミド誘導体類
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
AU7186094A (en) * 1993-06-30 1995-01-24 Ciba-Geigy Ag Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ace
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US5616775A (en) * 1994-05-05 1997-04-01 Bristol-Myers Squibb Co. Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US6929953B1 (en) * 1998-03-07 2005-08-16 Robert A. Levine Apparatus for analyzing biologic fluids
CA2332608C (en) 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EE05670B1 (et) 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2334671A1 (en) 2008-06-24 2011-06-22 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
BRPI1011657A2 (pt) 2009-05-28 2019-04-16 Novartis Ag derivados aminopropiônicos substituídos como inibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20150119107A (ko) 2013-02-14 2015-10-23 노파르티스 아게 개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334095A (en) * 1965-02-16 1967-08-01 Sandoz Ag Novel pyrrolo-oxazines and pyrrolo-oxazoles
US3334091A (en) * 1965-03-25 1967-08-01 Sandoz Ag Sedatives
GB1525845A (en) * 1976-07-30 1978-09-20 Ucb Sa 1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
IE50839B1 (en) * 1980-02-26 1986-07-23 Wyeth John & Brother Ltd Novel processes for preparing proline derivatives and analogous compounds
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
ZA833214B (en) * 1982-05-12 1983-12-28 Hoffmann La Roche Bicyclic compounds
US4552889A (en) * 1983-06-09 1985-11-12 Eli Lilly And Company 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
US4973585A (en) * 1986-06-13 1990-11-27 Merrell Dow Pharmaceuticals Tricyclic lactams active as antihypertensive agents
ZA874107B (es) * 1986-06-13 1987-12-09
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use
DE3901291A1 (de) * 1988-01-27 1989-08-03 Hoechst Ag Verbindungen mit psychotroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe von stoerungen des zentralen nervensystems
EP0331609A3 (de) * 1988-01-27 1992-07-01 Hoechst Aktiengesellschaft Angiotensin-Converting-Enzym-Hemmstoffe mit psychotroper Wirkung
HU904967D0 (en) * 1988-04-22 1991-01-28 Hoechst Ag Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives
GB8926512D0 (en) * 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
WO1991009840A1 (en) * 1989-12-22 1991-07-11 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
EP0492369B1 (en) * 1990-12-21 1997-09-17 Merrell Pharmaceuticals Inc. Novel amino and nitro containing tricyclic compounds useful as inhibitors of ace
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
EP0533084A1 (en) * 1991-09-16 1993-03-24 Schering Corporation Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5238932A (en) * 1992-05-20 1993-08-24 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase

Also Published As

Publication number Publication date
US5472959A (en) 1995-12-05
AU657794B2 (en) 1995-03-23
HU214596B (hu) 1998-04-28
ZA927211B (en) 1993-03-24
DK0534492T3 (da) 1997-01-06
ATE146482T1 (de) 1997-01-15
EP0534492A3 (en) 1993-06-09
NZ244442A (en) 1995-01-27
FI924312A0 (fi) 1992-09-25
GR3022654T3 (en) 1997-05-31
FI924312L (fi) 1993-03-28
IL103265A (en) 1996-09-12
JP3173673B2 (ja) 2001-06-04
DE69216026D1 (de) 1997-01-30
CA2078759A1 (en) 1993-03-28
NO923743D0 (no) 1992-09-25
EP0534492B1 (en) 1996-12-18
IL103265A0 (en) 1993-02-21
AU2524792A (en) 1993-04-01
HU9203076D0 (en) 1992-12-28
NO300844B1 (no) 1997-08-04
EP0534492A2 (en) 1993-03-31
KR100273734B1 (ko) 2001-02-01
NO923743L (no) 1993-03-29
HUT65174A (en) 1994-05-02
FI101304B (fi) 1998-05-29
KR930006026A (ko) 1993-04-20
JPH05213950A (ja) 1993-08-24
CA2078759C (en) 2003-09-16
FI101304B1 (fi) 1998-05-29
DE69216026T2 (de) 1997-07-17

Similar Documents

Publication Publication Date Title
ES2097847T3 (es) Inhibidores de encefalinasa y eca con un radical carboxialquilo.
ES2036551T3 (es) Compuestos heterociclicos.
ES8607970A1 (es) Un procedimiento para la obtencion de derivados de hexahidro-3-oxo-piridinas.
ES2132373T3 (es) Benzocicloheptenos, benzoxepinas y benzotiepinas.
ES2049256T3 (es) Composicion absorbente de gases acidos.
ES8703485A1 (es) Un procedimiento para preparar un derivado de acido pipera- zino-2-carboxilico
ES2114619T3 (es) Nuevos analogos de la vitamina d.
ES2117281T3 (es) Nuevos analogos de la vitamina d.
ES8106291A1 (es) Procedimiento para preparar derivados de 3-aminoproxiarilo
ES2003651A6 (es) Un procedimiento para la preparacion de derivados de 8-tia-1,6-diazabiciclo (4,3,0)-nonano.
ES463409A1 (es) Procedimiento para la preparacion de nuevas fluoracil-resor-cinas sustituidas.
ES2118333T3 (es) Derivados del acido naftilacetico como agonistas y antagonistas de pgez.
ES2059416T3 (es) 1,4-dihidropiridina-enantiomeros.
ES477520A1 (es) Procedimiento para la preparacion de nuevas penicilinas.
ES2032752T3 (es) Procedimiento de preparacion de derivados de la 1-bencenosulfonil-2-oxo-5-alcoxi-pirrolidina.
ES463803A1 (es) Procedimiento para la produccion de hidroxilaminas o-alqui- ladas.
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES8706148A1 (es) Un procedimiento para preparar nuevos derivados de carbapenem.
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
ES8102106A1 (es) Un procedimiento para preparar benzoxazepinas
ES463971A1 (es) Perfeccionamientos en o relacionados con compuestos organi- cos.
ES2038708T3 (es) Metodo para producir compuestos de benzotiepino(5,4-c)piridazina.
ES449430A1 (es) Procedimiento para preparar n-metilcarbamatos de 2, 3-dihi- drobenzofuranil-(7) n-sulfenilados.
ES2190222T3 (es) Derivados de 3-(2-oxo-(1,3')bipirrolindinil-3-iliden-metil)-cefem.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 534492

Country of ref document: ES